Bridging Innovation for Health
From key intermediates to formulation licenses — one accountable party delivers end-to-end
We reason backward from blockbuster drugs to decide which intermediate to make, produce it through a tiered supplier network, prove it with a quality-governance system, and deliver it compliantly via our overseas platform. Formulation licenses, APIs, intermediates and excipients — four categories delivered under one contract by one accountable party.
Recommended for Your Region
Molecules in strongest demand in your region, plus the local registration route
质量与文件要求高，一致性评价 / 关联审评是前置条件
NMPA / PMDA / MFDS 各自要求，登记人制度与 BE 要求严格；原料需关联审评审批平台登记
Three delivery tiers, by your stage of trust
Three tiers are not three price bands — they are three depths of collaboration. Start with tier one: judge us on one or two batches.
What we deliver: four categories
Every category is searchable, quotable, and annotated with registration status and document availability.
Why trust us
In cross-border sourcing the biggest cost isn't price — it's the cost of judging whether the other side is reliable. These four are checkable, one by one.
Overseas business platform + industrial investment & holding platform + core operating entity + a dozen specialized subsidiaries and partner companies.
Supplier audits & quality agreements, project quality loop (deviation → CAPA), original spectra and batch records archived together and traceable.
Structured demand → tech review → dispatch coordination → quality feedback → dossier assembly → project board — all six steps logged.
We reason backward from patent cliffs of blockbusters and generic filing pipelines to spot key-intermediate opportunities — explain 'why this one' before price.
How to start
Tell us the product or CAS, spec & quantity, and target country — we return a tech-review conclusion and a commercial proposal within 3 business days. No long-term agreement required first.